NEOADJUVANT MELANOMA

Clinical trials for NEOADJUVANT MELANOMA explained in plain language.

Never miss a new study

Get alerted when new NEOADJUVANT MELANOMA trials appear

Sign up with your email to follow new studies for NEOADJUVANT MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Terminated 1

New immune drug shows promise in early trial for Hard-to-Treat cancers

Disease control Ongoing

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

Matched conditions: NEOADJUVANT MELANOMA

Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control

Last updated Jun 27, 2026 09:07 UTC

NEOADJUVANT MELANOMA

Get alerted when new NEOADJUVANT MELANOMA trials appear

New immune drug shows promise in early trial for Hard-to-Treat cancers